US20130096187A1 - Pharmaceutical composition for external use - Google Patents

Pharmaceutical composition for external use Download PDF

Info

Publication number
US20130096187A1
US20130096187A1 US13/693,987 US201213693987A US2013096187A1 US 20130096187 A1 US20130096187 A1 US 20130096187A1 US 201213693987 A US201213693987 A US 201213693987A US 2013096187 A1 US2013096187 A1 US 2013096187A1
Authority
US
United States
Prior art keywords
pharmaceutical composition
composition
luliconazole
mass
external use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/693,987
Inventor
Hirokazu Kobayashi
Akira Nozawa
Katsumasa Ariyoshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Priority to US13/693,987 priority Critical patent/US20130096187A1/en
Assigned to POLA PHARMA INC., NIHON NOHYAKU CO., LTD. reassignment POLA PHARMA INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARIYOSHI, KATSUMASA, KOBAYASHI, HIROKAZU, NOZAWA, AKIRA
Publication of US20130096187A1 publication Critical patent/US20130096187A1/en
Priority to US15/342,525 priority patent/US20170071911A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to a pharmaceutical composition for external use, and more particularly, to a pharmaceutical composition for external use, which can be preserved in a state where a decrease in optical purity is suppressed.
  • the Japanese archipelago extends from a subtropical zone to a temperate zone and has a warm climate high in humidity, which is liable to facilitate propagation of fungi such as molds.
  • fungi such as molds.
  • due to westernization of clothes people are now accustomed to wearing shoes on feet. Accordingly, afoot serves as a favorable environment for the propagation of the fungi, leading to mycotic skin diseases that are serious social issues nowadays. Of those, onychomycosis has a low complete cure rate and high relapsing and reinfection rates. Therefore, an effective therapy has been demanded.
  • imidazole-based antifungal agents there are commercially available imidazole-based antifungal agents such as those represented by the general formula (1) described below, specifically, luliconazole represented by the structural formula (1) below and lanoconazole represented by the structural formula (2) below.
  • a commercially available product called “Lulicon” (registered trademark) is also present (e.g., see Patent Document 1 and Patent Document 2).
  • the luliconazole is an imidazole-based antifungal agent having optical activity with a wide antifungal spectrum, in particular, shows remarkable antifungal activity against dermatophytes.
  • the luliconazole is also characterized in that its retention in the stratum corneum is extremely high, and thus is a compound expected to be applied to treatment of onychomycosis.
  • luliconazole and lanoconazole are agents having problems in their solubility, so there is a need of using a solvent for their preparation.
  • the characteristic features of luliconazole may include a risk of a decrease in its optical purity when it is stored in a dissolved state under severe circumstances due to a type of a solvent used for dissolution, temperature, acid and base, or the like. Besides, such a decrease in optical purity may relate to a solvent.
  • a pharmaceutical composition for external use containing luliconazole and/or a salt thereof it is desirable to provide means for increasing the solubility thereof while suppressing a decrease in optical purity even under severe environment.
  • a decrease in optical purity is a common phenomenon, which sometimes occurs in an optically active compound according to storage conditions, particularly under severe conditions at high temperature.
  • no means for suppressing the phenomenon is known.
  • a pharmaceutical preparation containing luliconazole and/or a salt thereof a pharmaceutical preparation containing a film-forming agent and a polyoxypropylene/polyoxyethylene copolymer has been known (see, for example, Patent Document 6), but one containing N-methyl-2-pyrrolidone, propylene carbonate, or crotamiton has not been known at all.
  • Patent Document 7 a basic process for manufacturing an imidazole-based compound is also already known in the art (see, for example, Patent Document 7):
  • an object of the present invention is to provide a technique of dissolving luliconazole and/or a salt thereof (hereinafter, also referred to as “luliconazole or the like”) and preserving the luliconazole or the like in a state where a decrease in optical purity is suppressed.
  • the inventors of the present invention have made intensive studies and efforts to obtain a technique of dissolving luliconazole and/or a salt thereof and pre serving the luliconazole or the like in a state where a decrease in optical purity is suppressed and have finally completed the present invention by finding out that the luliconazole or the like can be stored in a state where a decrease in optical purity thereof is suppressed in addition to increase the solubility of the luliconazole or the like by dissolving the luliconazole or the like in an organic solvent, such as N-methyl-2-pyrrolidone, propylene carbonate, or crotamiton.
  • an organic solvent such as N-methyl-2-pyrrolidone, propylene carbonate, or crotamiton.
  • a pharmaceutical composition for external use including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) one or two or more selected from N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton.
  • a pharmaceutical composition for external use to be stored in a state in which luliconazole or the like is dissolved and prevented from a decrease in optical purity thereof can be provided.
  • the pharmaceutical composition for external use of the present invention contains as essential components luliconazole and/or a salt thereof.
  • the above-mentioned luliconazole is represented by the above-mentioned structural formula (1).
  • the above-mentioned luliconazole is a known compound represented by ( ⁇ )-(E)-[(4R)-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazolyl acetonitrile. Its manufacturing method and the antifungal properties are already known in the art. JP 62-93227 A (Patent Document 7 above) can be used as reference.
  • salt thereof is not specifically limited as far as it is physiologically acceptable.
  • Preferable examples thereof include: mineral acid salts such as hydrochloride, nitrate, sulfate, and phosphate; organic acid salts such as citrate, oxalate, lactate, and acetate; and sulfuric acid-containing salts such as mesilate and tosilate.
  • mineral acid salts such as hydrochloride, nitrate, sulfate, and phosphate
  • organic acid salts such as citrate, oxalate, lactate, and acetate
  • sulfuric acid-containing salts such as mesilate and tosilate.
  • hydrochloride is more preferable.
  • the content of luliconazole or the like is preferably 0.1 to 30% by mass, more preferably 0.5 to 15% by mass in total with respect to the total amount of the pharmaceutical composition.
  • the content of luliconazole or the like can be determined based on its solubility and formulation characteristics.
  • the pharmaceutical composition for external use of the present invention contains one or two or more organic solvents selected from N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton as an essential component.
  • organic solvent there may be used a single kind thereof or a combination of two or more kinds thereof.
  • the organic solvent of such a preferable aspect is excellent not only in action of dissolving luliconazole or a salt thereof but also in action of suppressing, in a dissolved state, a decrease in optical purity.
  • the total content of such a solvent is preferably 0.1 to 40% by mass, more preferably 1 to 10% by mass with respect to the total amount of the pharmaceutical composition.
  • the pharmaceutical composition for external use of the present invention can contain any of components commonly used in pharmaceutical compositions in addition to those described above, as far as it does not impair the effects of the present invention.
  • such components include: hydrocarbons such as vaseline and microcrystalline wax; esters such as jojoba oil and cetaceum; triglycerides such as beef tallow and olive oil; higher alcohols such as cetanol and oleyl alcohol; fatty acids such as stearic acid and oleic acid; alcohols such as ethanol and isopropanol; polyalcohols such as glycerin and 1,3-butanediol; water; non-ionic surfactants; anionic surfactants; cationic surfactants; amphoteric surfactants; thickeners such as polyvinyl pyrrolidone and carbopol; preservatives; UV absorbers; antioxidants; pigments; and powders.
  • hydrocarbons such as vaseline and microcrystalline wax
  • esters such as jojoba oil and cetaceum
  • triglycerides such as beef tallow and olive oil
  • higher alcohols such as cetanol and oleyl alcohol
  • fatty acids
  • a pharmaceutical composition for external use of the present invention is not specifically limited as far as it is formulated into any of forms used for pharmaceutical composition for external uses, and preferable examples thereof include lotions, emulsions, gelatinizing agents, cream pharmaceuticals, aerosols, nail enamel agents, and hide gel patches. Of those, the lotions are most preferable. For stabilizing the clarity and color of solution such as luliconazole, 50 to 90% by mass of ethanol is most preferably contained.
  • the pharmaceutical composition for external use of the present invention is preferably used for treating mycotic diseases or preventing progression of the diseases by using characteristics of luliconazole or the like.
  • the mycotic diseases include: foot trichophytosis such as athlete's foot; trichophytosis corporis such as candida and pityriasis versicolor; and trichophytosis on a hard keratin portion, such as onychomycosis. Because of remarkable effects, it is particularly preferable to use the pharmaceutical composition for external use of the present invention for treating the hard keratin portion, such as onychomycosis.
  • the pharmaceutical composition for external use of the present invention exerts preferable effects on the nail and such an effect is also exerted on typical dermatomycosis. Therefore, the application of a pharmaceutical composition for external use against dermatomycosis, which satisfies the configuration of the present invention, is also within the technical scope of the present invention.
  • Examples of such dermatomycosis include trichophytosis such as foot trichophytosis, particularly horny-outgrowing type hyperkeratotic trichophytosis which appears on heels or the like.
  • the present invention has a significant effect on the horny-outgrowing type hyperkeratotic trichophytosis, on which the conventional agents hardly exert their effects, among the above-mentioned dermatomycosis, which is preferable.
  • the pharmaceutical composition is applied on a diseased portion one or several times a day and the treatment is preferably carried out day after day.
  • the treatment is preferably carried out day after day.
  • onychomycosis luliconazole or the like, which is an effective component in an amount that cannot be attained by normal formulation, can be transferred into the nail. Therefore, onychomycosis can be treated only by the external application without having to drink an antifungal agent over a long period of time.
  • recurrence and reinfection have been a major problem for onychomycosis.
  • the recurrence and reinfection can be prevented by application of the pharmaceutical composition for external use of the present invention for 1 to 2 weeks after abatement of the symptom. Therefore, the pharmaceutical composition for external use of the present invention exerts preventive efficacy in this aspect.
  • a pharmaceutical composition for external use to be stored in a state where luliconazole or the like is dissolved and a decrease in optical purity thereof is suppressed can be provided.

Abstract

A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) crotamiton.
(−)-(E)-[(4R)-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazolyl acetonitrile
Figure US20130096187A1-20130418-C00001

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional of U.S. application Ser. No. 12/281,967, filed Sep. 5, 2008 which is the U.S. National Phase under 35 U.S.C. §371 of International Application PCT/JP2006/319708, filed Oct. 2, 2006, which was published in a non-English language, which claims priority to JP Patent Application No. 2006-062079, filed Mar. 8, 2006 and JP Patent Application No. 2006-215871 filed Aug. 8, 2006. The above applications are incorporated herein by reference.
    • TECHNICAL FIELD
  • The present invention relates to a pharmaceutical composition for external use, and more particularly, to a pharmaceutical composition for external use, which can be preserved in a state where a decrease in optical purity is suppressed.
    • BACKGROUND ART
  • The Japanese archipelago extends from a subtropical zone to a temperate zone and has a warm climate high in humidity, which is liable to facilitate propagation of fungi such as molds. In addition, due to westernization of clothes, people are now accustomed to wearing shoes on feet. Accordingly, afoot serves as a favorable environment for the propagation of the fungi, leading to mycotic skin diseases that are serious social issues nowadays. Of those, onychomycosis has a low complete cure rate and high relapsing and reinfection rates. Therefore, an effective therapy has been demanded.
  • Conventionally, treatments mainly using tolnaftate formulations have been conducted on such diseases. In recent years, imidazole-based antifungal agents, such as bifonazole and itraconazole, are mainly used.
  • As the imidazole-based antifungal agents, there are commercially available imidazole-based antifungal agents such as those represented by the general formula (1) described below, specifically, luliconazole represented by the structural formula (1) below and lanoconazole represented by the structural formula (2) below. A commercially available product called “Lulicon” (registered trademark) is also present (e.g., see Patent Document 1 and Patent Document 2).
  • The luliconazole is an imidazole-based antifungal agent having optical activity with a wide antifungal spectrum, in particular, shows remarkable antifungal activity against dermatophytes. In addition, the luliconazole is also characterized in that its retention in the stratum corneum is extremely high, and thus is a compound expected to be applied to treatment of onychomycosis. Like other imidazole-based antifungal agents, however, luliconazole and lanoconazole are agents having problems in their solubility, so there is a need of using a solvent for their preparation. On the other hand, in some cases, the characteristic features of luliconazole may include a risk of a decrease in its optical purity when it is stored in a dissolved state under severe circumstances due to a type of a solvent used for dissolution, temperature, acid and base, or the like. Besides, such a decrease in optical purity may relate to a solvent. In other words, with regard to a pharmaceutical composition for external use containing luliconazole and/or a salt thereof, it is desirable to provide means for increasing the solubility thereof while suppressing a decrease in optical purity even under severe environment.
  • A decrease in optical purity is a common phenomenon, which sometimes occurs in an optically active compound according to storage conditions, particularly under severe conditions at high temperature. However, no means for suppressing the phenomenon is known.
  • Heretofore, in a pharmaceutical technology for antifungal agents, various studies have been conducted for increasing the solubility thereof (see, for example, Patent Documents 3 to 5). However, the antifungal agents to be dissolved show increases different in their solubility. Therefore, the effect of one of them cannot be directly applied to the other compounds. Among the solvents, a solvent that acts to prevent the optically active compound from a decrease in optical purity has not yet been known.
  • On the other hand, as a pharmaceutical preparation containing luliconazole and/or a salt thereof, a pharmaceutical preparation containing a film-forming agent and a polyoxypropylene/polyoxyethylene copolymer has been known (see, for example, Patent Document 6), but one containing N-methyl-2-pyrrolidone, propylene carbonate, or crotamiton has not been known at all. In addition, a basic process for manufacturing an imidazole-based compound is also already known in the art (see, for example, Patent Document 7):
  • Figure US20130096187A1-20130418-C00002
  • General formula (1)
    where X represents a hydrogen atom or a chloride atom.
  • Figure US20130096187A1-20130418-C00003
    • Patent Document 1: JP 10-226686 A
    • Patent Document 2: JP 2-275877 A
    • Patent Document 3: JP 5-306223 A
    • Patent Document 4: JP 7-206711 A
    • Patent Document 5: WO96/11710
    • Patent Document 6: WO03/105841
    • Patent Document 7: JP 62-93227 A
    DISCLOSURE OF THE INVENTION Problem to be Solved by the Invention
  • The present invent has been made under such circumstances, and an object of the present invention is to provide a technique of dissolving luliconazole and/or a salt thereof (hereinafter, also referred to as “luliconazole or the like”) and preserving the luliconazole or the like in a state where a decrease in optical purity is suppressed.
    • Means for Solving the Problem
  • In consideration of such a situation, the inventors of the present invention have made intensive studies and efforts to obtain a technique of dissolving luliconazole and/or a salt thereof and pre serving the luliconazole or the like in a state where a decrease in optical purity is suppressed and have finally completed the present invention by finding out that the luliconazole or the like can be stored in a state where a decrease in optical purity thereof is suppressed in addition to increase the solubility of the luliconazole or the like by dissolving the luliconazole or the like in an organic solvent, such as N-methyl-2-pyrrolidone, propylene carbonate, or crotamiton. In other words, the present invention is as follows:
  • (1) A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) one or two or more selected from N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton.
  • Figure US20130096187A1-20130418-C00004
  • (2) A pharmaceutical composition for external use according to the item (1), in which the pharmaceutical composition for external use is provided for treatment or prevention of onychomycosis.
    • Effects of the Invention
  • According to the present invention, a pharmaceutical composition for external use to be stored in a state in which luliconazole or the like is dissolved and prevented from a decrease in optical purity thereof can be provided.
    • BEST MODE FOR CARRYING OUT THE INVENTION
  • (1) Luliconazole and/or a Salt Thereof as Essential Components of a Pharmaceutical Composition for External Use (Hereinafter, Referred to as Pharmaceutical Composition of the Present Invention)
  • The pharmaceutical composition for external use of the present invention contains as essential components luliconazole and/or a salt thereof. The above-mentioned luliconazole is represented by the above-mentioned structural formula (1). The above-mentioned luliconazole is a known compound represented by (−)-(E)-[(4R)-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazolyl acetonitrile. Its manufacturing method and the antifungal properties are already known in the art. JP 62-93227 A (Patent Document 7 above) can be used as reference.
  • In addition, “salt thereof” is not specifically limited as far as it is physiologically acceptable. Preferable examples thereof include: mineral acid salts such as hydrochloride, nitrate, sulfate, and phosphate; organic acid salts such as citrate, oxalate, lactate, and acetate; and sulfuric acid-containing salts such as mesilate and tosilate. In terms of safety and solubility, hydrochloride is more preferable.
  • In the pharmaceutical composition for external use of the present invention, the content of luliconazole or the like is preferably 0.1 to 30% by mass, more preferably 0.5 to 15% by mass in total with respect to the total amount of the pharmaceutical composition. The content of luliconazole or the like can be determined based on its solubility and formulation characteristics.
  • (2) Essential Component of Pharmaceutical Composition for external use of the present invention: N-methyl-2-pyrrolidone, propylene carbonate, or crotamiton
  • The pharmaceutical composition for external use of the present invention contains one or two or more organic solvents selected from N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton as an essential component. Obviously, for the organic solvent, there may be used a single kind thereof or a combination of two or more kinds thereof. In the pharmaceutical composition of the present invention, among the above organic solvents, it is preferable to contain at least N-methyl-2-pyrrolidone, particularly both N-methyl-2-pyrrolidone and propylene carbonate. The organic solvent of such a preferable aspect is excellent not only in action of dissolving luliconazole or a salt thereof but also in action of suppressing, in a dissolved state, a decrease in optical purity. For exerting such an action sufficiently, the total content of such a solvent is preferably 0.1 to 40% by mass, more preferably 1 to 10% by mass with respect to the total amount of the pharmaceutical composition.
  • (3) Pharmaceutical Composition for External Use of the Present Invention
  • The pharmaceutical composition for external use of the present invention can contain any of components commonly used in pharmaceutical compositions in addition to those described above, as far as it does not impair the effects of the present invention.
  • Preferable examples of such components include: hydrocarbons such as vaseline and microcrystalline wax; esters such as jojoba oil and cetaceum; triglycerides such as beef tallow and olive oil; higher alcohols such as cetanol and oleyl alcohol; fatty acids such as stearic acid and oleic acid; alcohols such as ethanol and isopropanol; polyalcohols such as glycerin and 1,3-butanediol; water; non-ionic surfactants; anionic surfactants; cationic surfactants; amphoteric surfactants; thickeners such as polyvinyl pyrrolidone and carbopol; preservatives; UV absorbers; antioxidants; pigments; and powders. Those optional components and the above-mentioned component are treated by common procedures, whereby a pharmaceutical composition for external use of the present invention can be produced. The pharmaceutical composition for external use of the present invention is not specifically limited as far as it is formulated into any of forms used for pharmaceutical composition for external uses, and preferable examples thereof include lotions, emulsions, gelatinizing agents, cream pharmaceuticals, aerosols, nail enamel agents, and hide gel patches. Of those, the lotions are most preferable. For stabilizing the clarity and color of solution such as luliconazole, 50 to 90% by mass of ethanol is most preferably contained.
  • The pharmaceutical composition for external use of the present invention is preferably used for treating mycotic diseases or preventing progression of the diseases by using characteristics of luliconazole or the like. The mycotic diseases include: foot trichophytosis such as athlete's foot; trichophytosis corporis such as candida and pityriasis versicolor; and trichophytosis on a hard keratin portion, such as onychomycosis. Because of remarkable effects, it is particularly preferable to use the pharmaceutical composition for external use of the present invention for treating the hard keratin portion, such as onychomycosis. In particular, the pharmaceutical composition for external use of the present invention exerts preferable effects on the nail and such an effect is also exerted on typical dermatomycosis. Therefore, the application of a pharmaceutical composition for external use against dermatomycosis, which satisfies the configuration of the present invention, is also within the technical scope of the present invention. Examples of such dermatomycosis include trichophytosis such as foot trichophytosis, particularly horny-outgrowing type hyperkeratotic trichophytosis which appears on heels or the like. The present invention has a significant effect on the horny-outgrowing type hyperkeratotic trichophytosis, on which the conventional agents hardly exert their effects, among the above-mentioned dermatomycosis, which is preferable.
  • With regard to its use, for example, the pharmaceutical composition is applied on a diseased portion one or several times a day and the treatment is preferably carried out day after day. In particular, for onychomycosis, luliconazole or the like, which is an effective component in an amount that cannot be attained by normal formulation, can be transferred into the nail. Therefore, onychomycosis can be treated only by the external application without having to drink an antifungal agent over a long period of time. In addition, recurrence and reinfection have been a major problem for onychomycosis. However, the recurrence and reinfection can be prevented by application of the pharmaceutical composition for external use of the present invention for 1 to 2 weeks after abatement of the symptom. Therefore, the pharmaceutical composition for external use of the present invention exerts preventive efficacy in this aspect.
    • EXAMPLES
  • Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to those examples.
    • Examples 1 to 6 and Comparative Examples 1 to 4
  • According to the formulation shown in Table 1, Pharmaceutical Preparations 1 to 6 each containing the pharmaceutical composition for external use of the present invention were prepared. That is, formulation components were stirred at room temperature and components for pharmaceutical preparation were then dissolved, thereby obtaining a pharmaceutical preparation of a clear lotion dosage form. Here, the value represents “% by mass”. Likewise, according to Table 2, Comparative Pharmaceutical Preparations 1 to 4 for the respective comparative examples were also prepared.
  • TABLE 1
    Pharmaceutical Preparations
    1 2 3 4 5 6
    Luliconazole 1 1 1 1 1 1
    N-methyl-2-pyrrolidone 5 8 5 8
    Propylene carbonate 5 10
    Crotamiton 5
    Squalane 5
    1,3-butylene glycol 20 25
    Concentrated glycerin 3
    Cetanol 0.75
    POE (10) hydrogenated castor oil 1
    POE (10) lauric acid 0.25
    Stearic acid monoglyceride 0.25
    Water 10 55.75
    Ethanol 94 94 94 81 64
  • TABLE 2
    Comparative
    Pharmaceutical
    Preparations
    1 2 3 4
    Luliconazole 1 1 1 1
    Dimethyl sulfoxide 5
    Methyl ethyl ketone 5
    Ethyl acetate 5
    Ethanol 94 94 94 99
    • Experimental Examples
  • Pharmaceutical Preparations 1 to 6 and Comparative Pharmaceutical Preparations 1 to 4 as described above were subjected to two-week storage experiments under conditions of 40° C. and 60° C. Immediately before and after the storage experiment, the amount of an SE body ((S)-(+)isomer) produced, which is an enantiomer of luliconazole, was measured by HPLC and expressed in area percentage to investigate the stability thereof. The results are shown in Table 3. Consequently, it can be recognized that any of the pharmaceutical composition for external uses of the present invention is stored in a state where a decrease in optical purity is suppressed.
    • <HPLC Conditions>
      • Instrument used: LC-97 system (Shimadzu Corporation)
      • Column: CHIRALPACK AD-H 4.6 mm×250 mm
      • Column temperature: 40° C.
      • Mobile phase: Water:acetonitrile=90:11 to 60:40 (30-minute gradient condition)
      • Flow rate: 0.8 ml/min
      • Detection: UV (300 nm in wavelength)
      • Quantitative assay: an area-percentage method using an absolute working curve
  • TABLE 3
    Stability (Increased
    amount of SE isomer)
    At start 40°, 2 Week 60°, 2 Week
    Pharmaceutical 0.16 1.11 3.03
    preparation 1
    Pharmaceutical 0.21 2.13 14.89
    preparation 2
    Pharmaceutical 0.15 0.55 5.79
    preparation 3
    Pharmaceutical 0.14 0.18 Not detected
    preparation 4
    Pharmaceutical 0.44 0.52 Not detected
    preparation 5
    Pharmaceutical 0.32 0.43 Not detected
    preparation 6
    Comparative 0.20 5.09 23.01
    preparation 1
    Comparative 0.23 8.69 32.73
    preparation 2
    Comparative 0.19 3.30 31.15
    preparation 3
    Comparative 0.16 8.70 41.68
    preparation 4
    • INDUSTRIAL APPLICABILITY
  • According to the present invention, a pharmaceutical composition for external use to be stored in a state where luliconazole or the like is dissolved and a decrease in optical purity thereof is suppressed can be provided.

Claims (20)

What is claimed is:
1. A pharmaceutical composition for external use, comprising:
i) (R)-luliconazole represented by the following structural formula (1) and/or a salt thereof; and
ii) crotamiton at a concentration of 0.1 to 40% by mass
Figure US20130096187A1-20130418-C00005
(−)-(E)-[(4R)-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazolyl acetonitrile Structural formula (1).
2. A pharmaceutical composition according to claim 1, wherein the composition comprises crotamiton in an amount of 1 to 10% by mass of the composition.
3. A pharmaceutical composition according to claim 1, wherein the composition comprises (R)-luliconazole in an amount of 0.5 to 15% by mass of the composition.
4. A pharmaceutical composition according to claim 1, wherein the composition further comprises ethanol.
5. A pharmaceutical composition according to claim 4, wherein the composition comprises ethanol in amount of 50 to 90% by mass of the composition.
6. A method of treating mycotic disease comprising externally administering the composition of claim 1 to an individual in need of treatment.
7. A method according to claim 6, wherein the mycotic disease is foot trichophytosis, trichophytosis corporis or trichophytosis on a hard keratin portion.
8. A method according to claim 6, wherein the mycotic disease is athlete's foot.
9. A method according to claim 6, wherein the mycotic disease is onychomycosis.
10. A method according to claim 6, wherein the mycotic disease is a mycotic disease of a nail.
11. A method according to claim 6, wherein the mycotic disease is dermatomycosis.
12. A pharmaceutical composition according to claim 2, wherein the composition comprises (R)-luliconazole in an amount of 0.5 to 15% by mass of the composition.
13. A pharmaceutical composition according to claim 2, wherein the composition further comprises ethanol.
14. A pharmaceutical composition according to claim 13, wherein the composition comprises ethanol in amount of 50 to 90% by mass of the composition.
15. A pharmaceutical composition according to claim 3, wherein the composition further comprises ethanol.
16. A pharmaceutical composition according to claim 15, wherein the composition comprises ethanol in amount of 50 to 90% by mass of the composition.
17. A pharmaceutical composition according to claim 12, wherein the composition further comprises ethanol.
18. A pharmaceutical composition according to claim 17, wherein the composition comprises ethanol in amount of 50 to 90% by mass of the composition.
19. A pharmaceutical composition for external use, consisting essentially of:
i) (R)-(−)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazolyl acetonitrile and/or a salt thereof; and
ii) crotamiton at a concentration of 0.1 to 40% by mass.
20. The pharmaceutical composition of any one of claims 1, 2, 3, 4, 12, or 14, wherein the pharmaceutical composition is formulated as a lotion.
US13/693,987 2006-03-08 2012-12-04 Pharmaceutical composition for external use Abandoned US20130096187A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/693,987 US20130096187A1 (en) 2006-03-08 2012-12-04 Pharmaceutical composition for external use
US15/342,525 US20170071911A1 (en) 2006-03-08 2016-11-03 Pharmaceutical composition for external use

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2006062079 2006-03-08
JP2006-062079 2006-03-08
JP2006215871 2006-08-08
JP2006-215871 2006-08-08
PCT/JP2006/319708 WO2007102242A1 (en) 2006-03-08 2006-10-02 External pharmaceutical composition
US28196708A 2008-09-05 2008-09-05
US13/693,987 US20130096187A1 (en) 2006-03-08 2012-12-04 Pharmaceutical composition for external use

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/JP2006/319708 Division WO2007102242A1 (en) 2006-03-08 2006-10-02 External pharmaceutical composition
US12/281,967 Division US8349882B2 (en) 2006-03-08 2006-10-02 Pharmaceutical composition for external use
US28196708A Division 2006-03-08 2008-09-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/342,525 Division US20170071911A1 (en) 2006-03-08 2016-11-03 Pharmaceutical composition for external use

Publications (1)

Publication Number Publication Date
US20130096187A1 true US20130096187A1 (en) 2013-04-18

Family

ID=38474687

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/281,967 Active 2027-04-26 US8349882B2 (en) 2006-03-08 2006-10-02 Pharmaceutical composition for external use
US13/693,987 Abandoned US20130096187A1 (en) 2006-03-08 2012-12-04 Pharmaceutical composition for external use
US15/342,525 Abandoned US20170071911A1 (en) 2006-03-08 2016-11-03 Pharmaceutical composition for external use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/281,967 Active 2027-04-26 US8349882B2 (en) 2006-03-08 2006-10-02 Pharmaceutical composition for external use

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/342,525 Abandoned US20170071911A1 (en) 2006-03-08 2016-11-03 Pharmaceutical composition for external use

Country Status (16)

Country Link
US (3) US8349882B2 (en)
EP (1) EP2005958B1 (en)
JP (1) JP5160409B2 (en)
KR (1) KR101343291B1 (en)
AU (1) AU2006339842B2 (en)
BR (1) BRPI0621446C1 (en)
CA (1) CA2645070C (en)
ES (1) ES2421613T3 (en)
IL (1) IL193894A (en)
MX (1) MX2008011435A (en)
NZ (1) NZ571819A (en)
PL (1) PL2005958T3 (en)
RU (1) RU2423128C2 (en)
TW (1) TWI389686B (en)
WO (1) WO2007102242A1 (en)
ZA (1) ZA200808531B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980931B1 (en) 2013-12-12 2015-03-17 Pola Pharma Inc. Method of evaluating pharmaceutical preparation containing luliconazole and index substance
US9012484B2 (en) 2012-09-14 2015-04-21 Pola Pharma Inc. Crystal and pharmaceutical preparation containing the same crystal
US9068958B1 (en) 2012-09-14 2015-06-30 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and pharmaceutical composition prepared by containing the crystal
US9145401B2 (en) 2012-09-14 2015-09-29 Pola Pharma Inc. Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation
US9453006B2 (en) 2013-03-08 2016-09-27 Pola Pharma Inc. Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
US9480746B2 (en) 2014-04-21 2016-11-01 Pola Pharma Inc. Resin container filled with antifungal pharmaceutical composition
US9527836B2 (en) 2013-09-06 2016-12-27 Pola Pharma Inc. Crystal having specific crystal habit and pharmaceutical composition containing the crystal as active ingredient
US10898470B1 (en) 2019-08-13 2021-01-26 Sato Pharmaceutical Co., Ltd. Pharmaceutical composition containing antifungal agent as active ingredient

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008011433A (en) 2006-03-08 2008-09-18 Nihon Nohyaku Co Ltd External pharmaceutical composition.
WO2007102242A1 (en) 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
EP2005959B1 (en) * 2006-03-08 2015-01-21 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
KR20100075475A (en) * 2007-09-05 2010-07-02 가부시키가이샤 폴라 파마 Pharmaceutical composition
CN101808639B (en) * 2007-09-05 2012-12-05 宝丽制药股份有限公司 Antifungal pharmaceutical composition
CN101808638B (en) 2007-09-05 2012-07-25 宝丽制药股份有限公司 Antifungal composition
ES2468540T3 (en) 2009-02-13 2014-06-16 Topica Pharmaceuticals, Inc Antifungal formulation
KR101409792B1 (en) * 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 Antimycotic pharmaceutical composition
EP2416757A2 (en) * 2009-04-09 2012-02-15 Pola Pharma Inc. Antimycotic pharmaceutical composition
EP2470178B1 (en) * 2009-08-25 2018-10-17 Pola Pharma Inc. Antimycotic pharmaceutical composition
WO2011155640A1 (en) * 2010-06-11 2011-12-15 Pola Pharma Inc. Antimycotic pharmaceutical composition
JP5980700B2 (en) * 2012-03-19 2016-08-31 株式会社ポーラファルマ Resin container filled with antifungal pharmaceutical composition
US9199977B2 (en) 2012-09-14 2015-12-01 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
JP5686874B2 (en) * 2012-09-14 2015-03-18 株式会社ポーラファルマ Pharmaceutical composition
JP6067399B2 (en) * 2013-02-08 2017-01-25 株式会社ポーラファルマ Pharmaceutical composition
JP5730340B2 (en) * 2013-02-08 2015-06-10 株式会社ポーラファルマ Reservoir type pharmaceutical composition
JP5662495B2 (en) * 2013-02-08 2015-01-28 株式会社ポーラファルマ Pharmaceutical composition in solubilizer form
JP6503626B2 (en) * 2013-03-28 2019-04-24 大正製薬株式会社 Pharmaceutical composition
JP6503627B2 (en) * 2013-03-28 2019-04-24 大正製薬株式会社 Pharmaceutical liquid composition
WO2014185542A1 (en) 2013-05-17 2014-11-20 Pola Pharma Inc. Pharmaceutical composition for treating vaginitis or pneumonia
JP6110839B2 (en) * 2014-12-04 2017-04-05 株式会社ポーラファルマ Pharmaceutical composition in solubilizer form
TR201714882A2 (en) 2017-10-03 2019-04-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Topical pharmaceutical compositions of luliconazole
CN112773762B (en) * 2019-11-08 2023-04-18 威智医药股份有限公司 External-use medicine composition and preparation method and application thereof
RU2738595C1 (en) * 2020-03-17 2020-12-14 Марина Михайловна Бурмина Therapeutic and cosmetic composition

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267169A (en) 1978-07-22 1981-05-12 Toko Yakuhin Kogyo Kabushiki Kaisha Novel preparation of clotrimazole
JPS5815909A (en) 1981-07-22 1983-01-29 Toko Yakuhin Kogyo Kk Antimycotic agent for external use
US4636520A (en) 1984-07-16 1987-01-13 Fujisawa Pharmaceutical Co., Ltd. Antifungal composition employing pyrrolnitrin in combination with an imidazole compound
JPH0236572B2 (en) 1984-11-13 1990-08-17 Hokuriku Pharmaceutical SUTEROIDOO177MONOESUTERUGANJUKURIIMUZAI
JPS6293227A (en) 1985-10-19 1987-04-28 Nippon Nohyaku Co Ltd Antimycotic agent
US4764381A (en) 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
JPH0774144B2 (en) 1986-03-12 1995-08-09 久光製薬株式会社 Skin composition containing urea
US5686489A (en) 1986-12-23 1997-11-11 Tristrata Technology, Inc. Alpha hydroxyacid esters for skin aging
JPH01246219A (en) 1988-03-25 1989-10-02 Nippon Nohyaku Co Ltd Antimycotic cream composition for external use
JPH01242525A (en) 1988-03-25 1989-09-27 Nippon Nohyaku Co Ltd Antifungal agent for external use
JP3030780B2 (en) 1988-12-29 2000-04-10 日本農薬株式会社 Optically active ketene dithioacetal derivative and method for producing the same
JPH02264723A (en) 1989-04-06 1990-10-29 Taisho Pharmaceut Co Ltd Antifungal agent
NZ233827A (en) 1989-05-26 1991-06-25 Abbott Lab Pharmaceutical composition comprising clarithromycin, triglyceride oil and stabilising agent
IL97012A0 (en) 1990-01-30 1992-03-29 Gist Brocades Nv Topical preparations for treating human nails
US5340836A (en) 1991-02-19 1994-08-23 Mark S. Reinhard Composition and method for treatment of vaginal yeast infections
FR2673537B1 (en) 1991-03-08 1993-06-11 Oreal USE OF HYDROPHILIC PENETRATION AGENTS IN DERMATOLOGICAL COMPOSITIONS FOR THE TREATMENT OF ONYCHOMYCOSES, AND CORRESPONDING COMPOSITIONS.
JP2555555B2 (en) 1991-07-03 1996-11-20 武田薬品工業株式会社 Antifungal topical formulation
JPH06199701A (en) 1992-12-29 1994-07-19 Lion Corp Anti-inflammatory analgesic agent for external use
JPH06211651A (en) 1993-01-12 1994-08-02 Hisamitsu Pharmaceut Co Inc Composition for treating nail trichophytosis
JPH0774144A (en) 1993-06-29 1995-03-17 Sony Corp Cleaning method for plasma apparatus
RO115109B1 (en) 1993-07-01 1999-11-30 Yamanouchi Europ Bv Stable composition containing retinoid
DE4337945A1 (en) * 1993-11-06 1995-05-11 Labtec Gmbh Plasters for the treatment of nail mycoses
JP2860748B2 (en) * 1993-12-24 1999-02-24 エスエス製薬株式会社 Stable hydrocortisone butyrate-containing cream
JP3803393B2 (en) 1994-01-12 2006-08-02 久光製薬株式会社 Nail ringworm treatment composition
JP3629283B2 (en) 1994-02-15 2005-03-16 ポーラ化成工業株式会社 Skin preparation
JP3081766B2 (en) 1994-05-06 2000-08-28 東興薬品工業株式会社 Keratin storage type antifungal external composition
GB9420355D0 (en) 1994-10-10 1994-11-23 Univ Nottingham Preparation of protein microspheres, films and coatings
AU3673195A (en) 1994-10-13 1996-05-06 Hisamitsu Pharmaceutical Co., Inc. External preparation for nail ringworm
SE9502244D0 (en) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
EP0839035B1 (en) 1995-07-08 2002-10-02 Nihon Nohyaku Co., Ltd. Antifungal agent, compound therefor, process for producing the same
CA2230448A1 (en) 1995-08-28 1997-03-06 Showa Yakuhin Kako Co., Ltd. Composition for local anesthesia
US5993787A (en) 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
JP4253047B2 (en) 1996-09-27 2009-04-08 杏林製薬株式会社 Film-forming antifungal composition
JP4227677B2 (en) 1996-12-10 2009-02-18 杏林製薬株式会社 Film-forming antifungal composition
JPH10226686A (en) 1996-12-10 1998-08-25 Nippon Nohyaku Co Ltd (r)-(e)-(4-substituted phenyl-1,3-dithiolan-2-iriden)-1-imidazole-acetonitrile derivative as optically active substance, antifungal agent and production of the same
WO2000001384A1 (en) 1998-07-01 2000-01-13 Lead Chemical Co., Ltd. Ketotifen preparation for percutaneous absorption
US5962536A (en) * 1998-07-31 1999-10-05 Komer; Gene Injectable propofol formulations
DE59911740D1 (en) 1998-09-10 2005-04-14 Bioequal Ag Muttenz TOPIC APPLICABLE AGENTS AGAINST NAIL MUSHROOM DISEASES
US20040208906A1 (en) 1999-07-12 2004-10-21 Daiichi Suntory Pharma Co., Ltd. Pharmaceutical composition for topical administration
JP2001064206A (en) * 1999-08-30 2001-03-13 Isp Japan Kk Percutaneous absorption-promoting composition
US7074392B1 (en) 2000-03-27 2006-07-11 Taro Pharmaceutical Industries Limited Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections
US6428654B1 (en) 2000-04-05 2002-08-06 Hercules Incorporated Fungicidal method
JP2002114680A (en) * 2000-07-31 2002-04-16 Nippon Nohyaku Co Ltd Antifungal agent
JP2002193755A (en) 2000-12-28 2002-07-10 Sansho Seiyaku Co Ltd Antidandruff and anti-itching hair cosmetic and hair- shampooing cosmetic
JP2002284702A (en) 2001-01-19 2002-10-03 Teika Seiyaku Kk Antifungal pharmaceutical preparation for external use
KR100423666B1 (en) 2001-02-07 2004-03-18 보령제약 주식회사 Composition of Antifungal Topical preparations
US6585963B1 (en) 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US20030017207A1 (en) 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
JP2002363070A (en) 2001-06-06 2002-12-18 Yuutoku Yakuhin Kogyo Kk Transdermal patch preparation
WO2003020248A1 (en) 2001-09-04 2003-03-13 Trommsdorff Gmbh & Co. Kg Arzneimittel Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
JP2003252798A (en) 2002-02-28 2003-09-10 Shiseido Co Ltd Antibacterial gel preparation
US8039452B2 (en) 2002-06-18 2011-10-18 Pola Pharma Inc. Antifungal medicinal compositions
US6846837B2 (en) 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
JP4387639B2 (en) 2002-07-16 2009-12-16 久光製薬株式会社 Transdermal absorption preparation
EP1545619B1 (en) 2002-09-05 2008-01-23 Galderma S.A. Solution for ungual application
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
CA2519705C (en) 2003-03-21 2013-07-02 Nexmed Holdings, Inc. Antifungal nail coat and method of use
ES2535045T3 (en) 2003-04-10 2015-05-04 Vanderbilt Royalty Sub L.P. Uses and compositions for capsaicin administration
US20070099932A1 (en) 2003-06-25 2007-05-03 Toshihiro Shirouzu External preparation for athlete's foot treatment
JP4431369B2 (en) 2003-11-21 2010-03-10 久光製薬株式会社 Antifungal aerosol topical preparation
JP4429035B2 (en) 2004-02-27 2010-03-10 久光製薬株式会社 Cream preparation for external use with enhanced keratin retention
JP3783104B2 (en) * 2004-03-31 2006-06-07 小林製薬株式会社 Antifungal composition for external use
JP4990617B2 (en) 2004-06-15 2012-08-01 久光製薬株式会社 Anti-inflammatory analgesic topical
JP4690672B2 (en) * 2004-07-20 2011-06-01 岩城製薬株式会社 Emulsion skin external preparation
JP3800232B2 (en) 2004-09-30 2006-07-26 小林製薬株式会社 Antifungal composition for external use
JP2006306734A (en) 2005-04-26 2006-11-09 Tsumura & Co External preparation blended with urea
CN101351227A (en) 2005-12-28 2009-01-21 帝国制药株式会社 Pharmaceutical composition for application to nail
MX2008011433A (en) 2006-03-08 2008-09-18 Nihon Nohyaku Co Ltd External pharmaceutical composition.
WO2007102242A1 (en) 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
EP2005959B1 (en) 2006-03-08 2015-01-21 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
WO2008075207A2 (en) 2006-04-04 2008-06-26 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
KR20100075475A (en) 2007-09-05 2010-07-02 가부시키가이샤 폴라 파마 Pharmaceutical composition
CN101808638B (en) 2007-09-05 2012-07-25 宝丽制药股份有限公司 Antifungal composition
CN101808639B (en) 2007-09-05 2012-12-05 宝丽制药股份有限公司 Antifungal pharmaceutical composition
ES2468540T3 (en) 2009-02-13 2014-06-16 Topica Pharmaceuticals, Inc Antifungal formulation
KR101409792B1 (en) 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 Antimycotic pharmaceutical composition
EP2416757A2 (en) 2009-04-09 2012-02-15 Pola Pharma Inc. Antimycotic pharmaceutical composition

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012484B2 (en) 2012-09-14 2015-04-21 Pola Pharma Inc. Crystal and pharmaceutical preparation containing the same crystal
US9068958B1 (en) 2012-09-14 2015-06-30 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and pharmaceutical composition prepared by containing the crystal
US9145401B2 (en) 2012-09-14 2015-09-29 Pola Pharma Inc. Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation
US9453006B2 (en) 2013-03-08 2016-09-27 Pola Pharma Inc. Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
US9527836B2 (en) 2013-09-06 2016-12-27 Pola Pharma Inc. Crystal having specific crystal habit and pharmaceutical composition containing the crystal as active ingredient
US8980931B1 (en) 2013-12-12 2015-03-17 Pola Pharma Inc. Method of evaluating pharmaceutical preparation containing luliconazole and index substance
US9085554B2 (en) 2013-12-12 2015-07-21 Pola Pharma Inc. Method of evaluating pharmaceutical preparation containing luliconazole and index substance
US9480746B2 (en) 2014-04-21 2016-11-01 Pola Pharma Inc. Resin container filled with antifungal pharmaceutical composition
US10898470B1 (en) 2019-08-13 2021-01-26 Sato Pharmaceutical Co., Ltd. Pharmaceutical composition containing antifungal agent as active ingredient
US11738006B2 (en) 2019-08-13 2023-08-29 Sato Pharmaceutical Co., Ltd. Pharmaceutical composition containing antifungal agent as active ingredient

Also Published As

Publication number Publication date
KR101343291B1 (en) 2013-12-18
EP2005958A4 (en) 2010-09-15
CA2645070C (en) 2014-02-04
ES2421613T3 (en) 2013-09-04
CA2645070A1 (en) 2007-09-13
EP2005958A1 (en) 2008-12-24
ZA200808531B (en) 2009-12-30
TW200744588A (en) 2007-12-16
KR20080111044A (en) 2008-12-22
JPWO2007102242A1 (en) 2009-07-23
US20090137651A1 (en) 2009-05-28
WO2007102242A1 (en) 2007-09-13
US8349882B2 (en) 2013-01-08
PL2005958T3 (en) 2013-11-29
TWI389686B (en) 2013-03-21
MX2008011435A (en) 2009-02-03
AU2006339842A1 (en) 2007-09-13
NZ571819A (en) 2011-04-29
IL193894A0 (en) 2009-09-22
RU2008139905A (en) 2010-04-20
BRPI0621446C1 (en) 2021-05-25
BRPI0621446A2 (en) 2011-12-13
JP5160409B2 (en) 2013-03-13
BRPI0621446B8 (en) 2021-02-02
EP2005958B1 (en) 2013-04-17
IL193894A (en) 2015-03-31
AU2006339842B2 (en) 2012-06-07
US20170071911A1 (en) 2017-03-16
RU2423128C2 (en) 2011-07-10
BRPI0621446B1 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
US8349882B2 (en) Pharmaceutical composition for external use
US8058303B2 (en) Pharmaceutical composition for external use
US8268876B2 (en) Pharmaceutical composition for external use
KR20070024543A (en) Antifungal drug delivery
WO2016182032A1 (en) Administration of azole antifungal agent to eyelid skin
US20170258746A1 (en) Acetic acid/thymol compositions and their use in the treatment of onychomycosis
JP2007084496A (en) Antifungal agent composition
US20160271121A1 (en) Antifungal combination therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: NIHON NOHYAKU CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOBAYASHI, HIROKAZU;NOZAWA, AKIRA;ARIYOSHI, KATSUMASA;SIGNING DATES FROM 20121205 TO 20121206;REEL/FRAME:029539/0705

Owner name: POLA PHARMA INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOBAYASHI, HIROKAZU;NOZAWA, AKIRA;ARIYOSHI, KATSUMASA;SIGNING DATES FROM 20121205 TO 20121206;REEL/FRAME:029539/0705

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION